“Revolutionizing Precision Medicine with Quantitative Imaging Biomarkers”
Oncoradiomics has developed an innovative imaging analysis software (RADIOMICSTM) enabling the extraction of unique quantitative image features from standard images to guide personalized cancer diagnosis and treatment. Exploiting the personalized information embedded in the images, the company develop products and services with the unique advantage of providing higher quality care for cancer patients while minimizing total treatment cost at the same time. This is achieved by providing non-invasive quantitative imaging biomarkers from standard existing images and decision support tools for the selection of the right diagnosis and the optimal therapeutic option and therefore avoiding unnecessary over- or under-treatments. Oncoradiomics aim is meet the challenges of the current 21st century healthcare market by finding the right treatment for the right patient whilst delivering high quality individualized healthcare. To enable this Oncoradiomics has two core proprietary technology platforms: RADIOMICSTM and DISTRIMTM.
RADIOMICS™ is an innovative imaging analysis software solution that enables the extraction of unique quantitative features (and associated radiomics signatures) from standard images (CT, PET, MR…) to guide personalized cancer treatment. DISTRIM™ allows the analysis of large amounts of images in a distributed fashion. Our mission is to enable the right cancer diagnose & treatment for the right patient with quantitative imaging.